Business Wire

Excelra Acquires BISC Global, Creating an International Bioinformatics Powerhouse With an Industry-Leading Platform and Service Offering.

Share

Excelra, a leading life science data and digital solutions provider, has acquired BISC Global, a bioinformatics and data analytics consulting company with offices across Europe and the USA. The acquisition creates an international powerhouse in consulting-led bioinformatics, with expertise in artificial intelligence, machine learning, and omics and next-generation sequencing data analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005464/en/

Excelra is a trusted partner to the world's top pharmaceutical and biotechnology companies, providing data, insight, and R&D technology services. Its interdisciplinary teams of biocurators, bioinformaticians, data scientists, and engineers deliver harmonized data, optimized analysis pipelines, and advanced applications to accelerate drug discovery and development.

BISC Global is a consulting-led platform and service provider specializing in bioinformatics, biostatistics, artificial intelligence, and machine learning. It provides data analysis, pipeline development, cloud computing, and data visualization services. It also offers next-generation platforms such as the Online Pipeline Platform (OP2), which supports streamlined analysis of bulk RNA-seq, single-cell RNA-seq, somatic variant calling, and germline variant calling data; and ImmunoRaptor, an analysis platform that makes it easy for researchers to manage and analyze immune repertoire sequencing data.

BISC Global's leadership believes the acquisition will expand bioinformatics innovation and benefit customers of both organizations. "We are excited about the acquisition by Excelra and are confident that the synergies between our two organizations will enable our consultants to provide best-in-class bioinformatics services to the life science industry," said BISC Global CEO Maarten Braspenning.

Excelra CEO Anandbir Singh Brar said, "The acquisition of BISC Global is a strategic move that enhances our capabilities and expands our reach in the bioinformatics field. The combined entity will be amongst the industry leaders in bioinformatics platforms and services, and will have a major positive impact on the future of bioinformatics and the life science industry."

The acquisition creates a game-changing bioinformatics powerhouse, committed to driving innovation at the intersection of science and technology.

About Excelra

Excelra provides data, insight, and R&D technology services to the world's top pharmaceutical and biotech companies. From offices in Boston, Utrecht, London, and Hyderabad, Excelra's 1000+ domain experts operate at the intersection of science and technology to empower life science innovation and accelerate drug discovery and development. Excelra provides integrated solutions from data to insight. It starts by structuring and harmonizing diverse scientific data sets. Then it builds custom R&D data engineering, cloud infrastructure solutions, tailored computational models, and optimized analysis pipelines to lead the way to groundbreaking discoveries. For more information, visit excelra.com.

About BISC Global

Founded in 2017, BISC Global has grown to be a Top 10 Bioinformatics Consulting and Services Firm, supporting the world's leading pharmaceutical and biotech companies. BISC provides data analytics, custom tool/pipeline development, and cloud solutions delivered on-site or remotely. It has a global workforce of expert consultants, operating from offices in Ghent, Belgium; Basel, Switzerland; Amsterdam, The Netherlands; Boston, MA; and San Francisco, CA. BISC supports analysis across multiple domains, including machine learning (data mining, pattern recognition, image analysis, (un)supervised learning, neural networks, deep learning, etc.), bioinformatics (single-cell transcriptomics, metabolomics, metagenomics, epigenomics, etc.), and statistics (experimental design, mathematic modeling, signal-to-noise enhancement, and independent data cross-validation). For more information, visit biscglobal.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jigesh Shah
Jigesh.shah@excelra.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nanochon closes $4M Series Seed Prime6.5.2024 18:00:00 EEST | Press release

Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round. The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others. Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team. “We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care.” Nanochon will initiate a phase I trial in the US this year for its patented knee implant Chondrograft™. The device requires only minimally invasive surgery to regrow damaged cartilag

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies6.5.2024 17:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland. The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies. “We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collabo

NanoTemper Brings Spectral Shift Technology to the Protein Production Market With Andromeda X, Enabling Biopharma and CROs to Increase Efficiency of Expression Screening for Recombinant Protein Targets6.5.2024 16:17:00 EEST | Press release

NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein production market with the release of Andromeda X, an instrument that determines optimal expression alongside thermal stability of recombinant proteins in crude lysates. Andromeda X increases the efficiency of protein production teams at Biopharma and CROs, who now have the ability to optimize purification schemes for challenging, low-yield targets much faster, and with unprecedented insights on thermal stability during expression screening. “At NanoTemper, our vision of creating a world where every disease is treatable starts here, in early drug development. Without high-quality drug targets or protein therapeutics, researchers cannot realize this vision. So, we’ve adapted our reliable and trusted optics systems to provide valuable insights for those working to express and purify these critical t

Yubico’s Key Product Innovations Empower Enterprise Security and Phishing-Resistant Passwordless Authentication at Scale6.5.2024 16:00:00 EEST | Press release

Today Yubico (NASDAQ: YUBICO), the leading provider of hardware authentication security keys, announced the upcoming release of YubiKey 5.7 firmware for the YubiKey 5 Series, Security Key Series and Security Key Series - Enterprise Edition. With a focus on enterprise needs, these updates reinforce Yubico’s commitment to providing secure, simple, and scalable authentication solutions. Security keys with firmware 5.7 will be available to purchase in late May 2024, offering enhanced features such as improved PIN complexity, enterprise attestation, and expanded passkey credentials storage. These updates empower organizations to adopt passwordless-first, modern authentication, fostering phishing-resistant users worldwide. As part of Yubico’s goal of helping enterprises raise the bar for security with greater flexibility, the company also announced the availability of Yubico Authenticator 7 which will support the upcoming YubiKey 5.7 features. “Organizations are continuing to face a surge in

ATMECS Global Accelerates AI Innovation by Joining the NVIDIA Partner Network as Solution Advisor Consultant.6.5.2024 16:00:00 EEST | Press release

ATMECS Global, renowned for its prowess in digital transformation and engineering solutions, proudly announces that it has joined the NVIDIA Partner Network as a Solution Advisor Consultant. The milestone marks a pivotal step in ATMECS’s journey to redefine the AI and ML landscape, amplifying its commitment to innovation and excellence in delivering next-generation AI solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506918366/en/ Lori Banas-Chief AI/ML Officer (Photo: Business Wire) ATMECS will support customers in building and deploying a broad range of NVIDIA-powered solutions — including through the use of the NVIDIA Omniverse development platform for industrial digital twins, generative AI with NVIDIA NIM inference microservices and the NVIDIA AI Enterprise platform for cloud and on-premises deployments, as well as the NVIDIA Jetson platform for accelerated edge AI and robotics. Lori Banas, Chief AI/ML Office

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye